Results 1 to 10 of about 2,566,374 (138)

Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review. [PDF]

Pharmaceuticals (Basel), 2023
Urate-lowering therapies for the management of gout lead to a reduction in serum urate levels, monosodium urate crystal deposition, and the clinical features of gout, including painful and disabling gout flares, chronic gouty arthritis, and tophi.
Tabi-Amponsah AD, Stewart S, Hosie G, Stamp LK, Taylor WJ, Dalbeth N.   +5 more
europepmc   +5 more sources

Controversies in Urate-Lowering Therapy for Gout: A Comprehensive Review. [PDF]

Gout Urate Cryst Depos Dis
Gout is the most common inflammatory arthritis. Treatment of gout includes anti-inflammatory and urate-lowering agents. Robust guidelines by the American College of Rheumatology, the European Alliance of Associations for Rheumatology and other committees
Toprover M, Pillinger MH.
europepmc   +3 more sources

Urate-lowering therapy modifies associations between urinary urate and kidney outcome. [PDF]

Ren Fail
Background Serum uric acid is associated with chronic kidney disease (CKD) progression; however, causality remains uncertain. Although renal urate handling, rather than merely hyperuricemia, may dominate kidney outcomes, the prognostic value of urinary ...
Takata T, Mae Y, Hoi S, Otani N, Sugihara T, Hisatome I, Isomoto H.   +6 more
europepmc   +2 more sources

Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England. [PDF]

Rheumatology (Oxford), 2023
Russell MD, Roddy E, Rutherford AI, Ellis B, Norton S, Douiri A, Gulliford MC, Cope AP, Galloway JB.   +8 more
europepmc   +2 more sources

Revisiting the Ethics of Urate-Lowering Therapy Clinical Trials for Gout Management. [PDF]

Arthritis Rheumatol
The early 2000s saw a wave of randomized controlled trials (RCTs) of new urate-lowering therapies (ULTs) used in the management of gout. These trials compared the novel medications with placebo or relatively low doses of allopurinol.
Stamp LK, Ho D, Dalbeth N.
europepmc   +3 more sources

Expert consensus on urate‑lowering therapy for high‑risk hyperuricemia (2026 edition). [PDF]

Chin Med J (Engl)
Zhu X, Mo Y, Duan L, Qing Y, Dai L, Zhang Z, Zhao Y, Zou H.   +7 more
europepmc   +1 more source

Urate-lowering therapy for patients with gout on hemodialysis. [PDF]

Int J Rheum Dis, 2022
Alkilany R, Einstadter D, Antonelli M.
europepmc   +1 more source

Beliefs of rheumatologists and general practitioners on urate lowering therapy: a cross-sectional study. [PDF]

Rheumatol Adv Pract, 2023
Veenstra F, Vriezekolk JE, van den Bemt BJF, Schers HJ, Sloot B, van den Ende CHM, van Herwaarden N, Flendrie M.   +7 more
europepmc   +1 more source

Urate-lowering therapy in cardiovascular pharmacotherapy: from Mendelian randomization data to cardio-renal-metabolic risk modulation. [PDF]

Eur Heart J Cardiovasc Pharmacother
Borghi C, Fogacci F, Cicero AFG.
europepmc   +1 more source

Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions. [PDF]

Br J Clin Pharmacol, 2022
Coleshill MJ, Day RO, Tam K, Kouhkamari M, Caillet V, Aung E, Kannangara DRW, Cronin P, Rodgers A, Stocker SL.   +9 more
europepmc   +1 more source